drugset
drugset / Trial / NCT00722098

Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients

NCT00722098 ↗

Phase 2 Terminated 9 enrolled Baylor Research Institute
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether the combination of chemotherapy (Cyclophosphamide) and CD34-DC vaccines results in the improved rate of clinical responses for stage IV melanoma patients.

Timeline

Start
2008-06
Primary completion
2011-04
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 300 mg/m2 Intravenous
Subject DC vaccine Vaccine 1.5e+07 cells Subcutaneous

Indications

metastatic melanoma